Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Accenture
QuintilesIMS
US Department of Justice
Cantor Fitzgerald
Argus Health
Farmers Insurance
McKesson
Dow

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204083

« Back to Dashboard

NDA 204083 describes DESVENLAFAXINE SUCCINATE, which is a drug marketed by Actavis Labs Fl, Alembic Pharms Ltd, Lupin Ltd, Mylan Pharms Inc, Sandoz Inc, West-ward Pharms Int, and Zydus Pharms Usa Inc, and is included in eight NDAs. It is available from seven suppliers. Additional details are available on the DESVENLAFAXINE SUCCINATE profile page.

The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
Summary for 204083
Tradename:DESVENLAFAXINE SUCCINATE
Applicant:West-ward Pharms Int
Ingredient:desvenlafaxine succinate
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 204083
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204083 ANDA West-Ward Pharmaceuticals Corp. 0054-0401 0054-0401-13 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0054-0401-13)
DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204083 ANDA West-Ward Pharmaceuticals Corp. 0054-0401 0054-0401-22 90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0054-0401-22)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrengthEQ 100MG BASE
Approval Date:Feb 16, 2016TE:ABRLD:No
Regulatory Exclusivity Expiration:Aug 28, 2017
Regulatory Exclusivity Use:PATENT CHALLENGE

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Citi
Mallinckrodt
Daiichi Sankyo
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Cerilliant
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot